Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors

Human Pathology

Volumn 40, Issue 7, 2009, Pages 965-974

  Yasunaga, Masafumi ^a   Ohishi, Yoshihiro ^a,c   Oda, Yoshinao ^a   Misumi, Munechika ^b   Iwasa, Atsuko ^a   Kurihara, Shuichi ^a   Nishimura, Izumi ^a   Okuma, Emi ^a   Kobayashi, Hiroaki ^b   Wake, Norio ^b   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY BEPPU HOSPITAL   (Japan)

Author keywords

Immunophenotype; Low grade endometrioid tumor; Mullerian mucinous borderline tumor; Ovary; Serous borderline tumor

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; VIMENTIN; WT1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; GASTROINTESTINAL TUMOR; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MIXED MULLERIAN TUMOR; MUCINOUS CARCINOMA; OVARY TUMOR; PROTEIN EXPRESSION; TUMOR VOLUME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, ENDOMETRIOID; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; VIMENTIN; WT1 PROTEINS;

EID: 67349126474     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.12.006     Document Type: Article

References (38)

1. Rutgers J.L., and Scully R.E. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy: a clinicopathologic analysis. Cancer 61 (1988) 340-348
2. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon, France
3. Shappell H.W., Riopel M.A., Smith Sehdev A.E., et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed-cell type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 26 (2002) 1529-1541
4. Shih I.e.M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
5. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod pathol 18 (2005) S19-S32
6. Feeley K.M., and Wells M. Precursor lesions of ovarian epithelial malignancy. Histopatology 38 (2001) 87-95
7. Fukunaga M., and Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod Pathol 11 (1998) 784-788
8. Lehman M.B., and Hart W.R. Simple and complex hyperplastic papillary proliferations of the endometrium: a clinicopathologic study of nine cases of apparently localized papillary lesions with fibrovascular stromal cores and epithelial metaplasia. Am J Surg Pathol 25 (2001) 1347-1354
9. Lee K.R., and Nucci M.R. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol 22 (2002) 42-51
10. Catasus L., Bussaglia E., Rodriguez I., et al. Molecular genetic alterations in endometrioid carcinomas of the ovary; similar frequency of beta-catenin abnormalities but lower rates of microsatellite instability and PTEN alterations than in endometrioid carcinomas. Hum Pathol 35 (2004) 1360-1368
11. Sarrio D., Moreno-Bueno G., Sanchez-Estevez C., et al. Expression of cadherins and catenins correlates with distinct histologic type of ovarian carcinomas. Hum Pathol 37 (2006) 1042-1049
12. Ilyas M. Wnt signaling and the mechanistic basis of tumor development. J Pathol 205 (2005) 130-144
13. Saegusa M., and Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol 194 (2001) 59-67
14. Kurose K., Zhou X.P., Araki T., et al. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158 (2001) 2097-2106
15. Rutgers J.L., and Scully R.E. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type: a clinicopathologic analysis. Cancer 61 (1988) 546-554
16. Dabbs D.J., Sturtz K., and Zaino R.J. The immunohistochemical discrimination of endometrioid adenocarcinoma. Hum Pathol 27 (1996) 172-177
17. Mohsin S.K., Weiss H., Harighurst T., et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17 (2004) 1545-1554
18. Dube V., Roy M., Plante M., et al. Mucinous ovarian tumors of Mullerian type: an analysis of 17 cases including borderline tumors and intraepithelial, microinvasive and invasive carcinomas. Int J Gynecol Pathol 24 (2005) 138-146
19. Abu-Jawdeh G.M., Jacobs T.W., Niloff J., et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 60 (1996) 301-307
20. Vang R., Gown A.M., Barry T.S., et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 25 (2006) 83-89
21. Castrillon D.H., Lee K.R., and Nucci M.R. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 21 (2001) 4-10
22. Viale G., Gambacorta M., Dell'Orto P., et al. Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunohistochemical study of eighty-three cases. Virchow Archiv A Pathol Anat Histopathol 413 (1998) 91-101
23. Nictolis M., Montironi R., Tommasoni S., et al. Benign, borderline and well-differentiated malignant intestinal mucinous tumors of the ovary: a clinicopathologic, histochemical, immunohistochemical and nuclear quantitative study of 57 cases. Int J Gynecol Pathol 13 (1994) 10-21
24. Dabbs D.J., and Geisinger K.R. Common epithelial ovarian tumors: immunohistochemical intermediate filament profiles. Cancer 62 (1988) 368-374
25. Bell K.A., and Kurman R.J. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol 24 (2000) 1465-1479
26. Chen S., Leitao M.M., Tornos C., et al. Invasive pattern in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 18 (2005) 903-911
27. Al-Hussaini M., Stockman A., Foster H., et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44 (2004) 109-115
28. Oliva E., Sarrio D., Brachtel E.F., et al. High frequency of beta-catenin mutations in borderline endometrioid tumor of the ovary. J Pathol 208 (2006) 708-713
29. Gamallo C., Palacios J., Moreno G., et al. beta-Catenin expression pattern in stage I and II ovarian carcinomas: relationship with beta-catenin gene mutations, clinicopathologic features, and clinical outcome. Am J Pathol 155 (1999) 527-536
30. Obata K., Morland S.J., Watson R.H., et al. Frequent PTEN/MMAC mutation in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58 (1998) 2095-2097
31. Brachtel E.F., Sanchez-Estevez C., Moreno-Bueno G., et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Pathol 29 (2005) 1322-1329
32. Saegusa M., Hashimura M., Kuwata T., et al. Beta-catenin simultaneously induces activation of the p53-p21WAF1 pathway and overexpression of cyclin D1 during squamous differentiation of endometrial carcinoma cells. Am J Pathol 164 (2004) 1739-1749
33. Dinulescu D.M., Ince T.A., Quade B.J., et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11 (2005) 63-70
34. Sato N., Tsunoda H., Nishida M., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression form benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60 (2000) 7053-7056
35. Ali-Fehmi R., Khahifeh I., Bandyopadhyay S., et al. Patterns of loss of heterozygosity of 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising is association with endometriosis. Int J Gynecol Pathol 25 (2006) 223-229
36. Vigano P., Somigliana E., Chiodo I., et al. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. Hum Repod Update 12 (2006) 77-89
37. Martini M., Ciccarone M., Garganese G., et al. Possible involvement of hMLH1, 16 (INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 102 (2002) 398-406
38. Scotti S., Regidor P.A., Schindler A.E., et al. Reduced proliferation and cell adhesion in endometriosis. Mol Human Rep 6 (2000) 610-617